Podcasts about results overall

Ross Branch makes a move and grabs one more stage wind for the 2024 Dakar Rally. Ricky and Adrien bringin up 2 and 3. Plus, stage 12 preview, the final stage at the 2024 Dakar Rally Powered by: MotoMinded https://bit.ly/3TJMymm Mira Active Wear Fund Raiser: https://miraactivewear.co.za/win-a-suit/ Check out the fundraiser running now through February 2024! *The Banana Slicer https://amzn.to/3TZ69Py Trust us, just read the reviews! *Check Out EcoFlow: https://bit.ly/48bHb3Z (https://bit.ly/48bHb3Z)The River Pro is at the heart of the operations out in the field and at home because power loss sucks! *Rent a Bike on Twisted Road https://bit.ly/3H4mqva (https://bit.ly/3H4mqva) Offering up to 1 free day on trips of 4 or more days Thank you for tuning in to Chasing Waypoints Podcast! Like what you heard? Don't forget to hit that subscribe button and do not miss an episode! Also, you can follow us on Facebook (Chasing Waypoints) or Instagram (@chasingwaypoints) Want to participate? Check the Facebook page for your favorite episode and comment, we want to hear from you! Intro Music: Raise Your Shoes - Splasher! *Affiliate link: At no cost to you we get a small commission to help support the channel when you make a qualifying purchase! Thank you! --- Support this podcast: https://podcasters.spotify.com/pod/show/chasing-waypoints/support

Stage 3 is in the books, although some bikes still out there the top spots have been occupied! Powered by: MotoMinded https://bit.ly/3TJMymm Mira Active Wear Fund Raiser: https://miraactivewear.co.za/win-a-suit/ Check out the fundraiser running now through February 2024! *Check Out EcoFlow:https://bit.ly/48bHb3ZThe River Pro is at the heart of the operations out in the field and at home because power loss sucks! *Rent a Bike on Twisted Roadhttps://bit.ly/3H4mqva Offering up to 1 free day on trips of 4 or more days Interested in promoting your brand or event to a worldwide audience? Email us at:⁠Podcast@ChasingWaypoints.com⁠ ⁠www.ChasingWaypoints.com⁠ Thank you for tuning in to Chasing Waypoints Podcast! Like what you heard? Don't forget to hit that subscribe button and do not miss an episode! Also, you can follow us on Facebook (Chasing Waypoints) or Instagram (@chasingwaypoints) Want to participate? Check the Facebook page for your favorite episode and comment, we want to hear from you! Intro Music: Raise Your Shoes - Splasher! Outro Music: Like it Like This - Pink Laundry  *Affiliate link: At no cost to you we get a small commission to help support the channel when you make a qualifying purchase! Thank you! --- Support this podcast: https://podcasters.spotify.com/pod/show/chasing-waypoints/support

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.03.27.534331v1?rss=1 Authors: Diao, Y., Jelescu, I. O. Abstract: Background: The pathological process of Alzheimer's disease (AD) typically takes up decades from onset to clinical symptoms. Early brain changes in AD include MRI-measurable features such as aItered functional connectivity (FC) and white matter degeneration. The ability of these features to discriminate between subjects without a diagnosis, or their prognostic value, is however not established. Methods: The main trigger mechanism of AD is still debated, although impaired brain glucose metabolism is taking an increasingly central role. Here we used a rat model of sporadic AD, based on impaired brain glucose metabolism induced by an intracerebroventricular injection of streptozotocin (STZ). We characterized alterations in FC and white matter microstructure longitudinally using functional and diffusion MRI. Those MRI-derived measures were used to classify STZ from control rats using machine learning, and the importance of each individual measure was quantified using explainable artificial intelligence methods. Results: Overall, combining all the FC and white matter metrics in an ensemble way was the best strategy to discriminate STZ rats, with a consistent accuracy over 0.85. However, the best accuracy early on was achieved using white matter microstructure features, and later on using FC. This suggests that consistent damage in white matter in the STZ group might precede FC. For cross-timepoint prediction, microstructure features also had the highest performance while, in contrast, that of FC was reduced by its dynamic pattern which shifted from early hyperconnectivity to late hypoconnectivity. Conclusions: Our study highlights the MRI-derived measures that best discriminate STZ vs control rats early in the course of the disease, with potential translation to humans. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

It's time for another one of our infamous & patented Care/Don't Care Podcasts, with your talent: Eugene S. Robinson, John Nash, & Stephie Haynes.UFC VEGAS 66 RESULTS – Overall, this now 13-bout card saw two exciting first round finishes, four thrilling KO/TKO's, one sweet sub, and seven hard-fought decisions. Rounding things out, our fighters who were awarded for putting forth BONUS efforts included — POTN: Alex Caceres, & Michal Oleksiejczuk. FOTN: Drew Dober vs. Bobby Green.Here's a look at the UFC Vegas 66 fight card, updated records & full results from the event —FIGHT NIGHT MAIN CARD | 7/4PM ETPT13. Jared Cannonier (16-6) DEF. Sean Strickland (25-5) — via split decision (49-46, 46-49, 49-46)12. Arman Tsarukyan (19-3) DEF. Damir Ismagulov (24-2) — via unanimous decision (30-27, 30-27, 30-27)11. Amir Albazi (16-1) DEF. Alessandro Costa (12-3) — via KO (uppercut) at 2:13 of Round 310. Alex Caceres (20-13) DEF. Julian Erosa (28-10) — via TKO (left high kick) at 3:04 of Round 19. Drew Dober (26-11) DEF. Bobby Green (29-14) — via KO (left hand) at 2:45 of Round 28. Michal Oleksiejczuk (18-5) DEF. Cody Brundage (8-3)— via TKO (strikes) at 3:16 of Round 1PRELIMS7. Cory McKenna (8-2) DEF. Cheyanne Vlismas (7-3) — via unanimous decision (29-28, 29-28, 29-28)6. Matthew Semelsberger (11-4) DEF. Jake Matthews (18-6) — via unanimous decision (30-27, 29-28, 29-28)5. Said Nurmagomedov (17-2) DEF. Saidyokub Kakhramonov (10-3) — via submission (modified guillotine choke) at 3:50 of Round 24. Rafa Garcia (15-3) DEF. Hayisaer Maheshate (9-2) — via unanimous decision (30-27, 30-27, 30-27) 3. Rinat Fakhretdinov (21-2) DEF. Bryan Battle (8-2) — via unanimous decision (30-25, 30-25, 30-27)2. Manel Kape (18-6) DEF. David Dvořák (20-5) — via unanimous decision (30-27, 30-27, 29-28)1. Sergey Morozov (19-5) DEF. Journey Newson (10-4) — via unanimous decision (30-27, 29-28, 29-28)_____________UFC Vegas 67: ‘Imavov vs Gastelum' PICKS —At this point in the show we offer you our ‘disclaimer', then our trio will go about predicting the UFC Vegas 67 Fight Night bout sheet. This first event of the new year will take place from the APEX Facility in Vegas, on Sat, Jan 14th., 2023.Here's a look at the fight card & records for the upcoming event via tapology.com, bout order subject to change...UFC Vegas 67 (15 Cares):ESPN+ MAIN CARD | SAT. JAN. 14 — 7/4PM ETPT (12 CARES)12. Main Event - 185lbs: Kelvin Gastelum (17-8) vs. Nassourdine Imavov (12-3) — At 25:39, 2 Cares (Stephie & Eugene, John abstains on principal)11. Co-Main - 145lbs: Dan Ige (15-6) vs. Damon Jackson (22-4) — At 24:30, 2 Cares (Stephie & Eugene)10. 185lbs: Punahele Soriano (9-2) vs. Roman Kopylov (9-2) — At 21:01, 2 Cares (Eugene & Stephie)9. 135lbs: Ketlen Vieira (13-2) vs. Raquel Pennington (14-8) — At 18:22, 3 Cares8. 135lbs: Umar Nurmagomedov (15-0) vs. Raoni Barcelos (17-3) — At 15:19, 3 CaresESPN+ PRELIMS | 4PM/1PM ETPT (3 Cares)7. 185lbs: Abdul Razak Alhassan (11-5) vs. Claudio Ribeiro (10-2) — At 14:016. 155lbs: Mateusz Rębecki (16-1) vs. Nick Fiore (6-0) — At 12:145. 135lbs: Mateus Mendonça (10-0) vs. Javid Basharat (13-0) — At 10:37, 1 Care (Stephie)4. 125lbs: Allan Nascimento (19-6) vs. Carlos Hernandez (8-1) — At 10:223. 145lbs: Daniel Argueta (8-1) vs. Isaac Dulgarian (5-0) — At 8:532. 125lbs: Jimmy Flick (16-5) vs. Charles Johnson (12-3) — At 7:56, 1 Care (Eugene)1. 135lbs: Priscila Cachoeira (12-4) vs. Sijara Eubanks (7-7) — At 5:39, 1 Care (Eugene)_____________________At 29:13 — BONUS OFF TOPIC SEGMENT (Re: Dana White slapping his wife)_____________________Be sure to follow Eugene on twitter @EugeneSRobinson, John is @heynottheface, and of course you can catch Stephie @CrooklynMMA, and twice a week she's on @LevelChangePod. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit bloodyelbowpodcast.substack.com/subscribe This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit bloodyelbowpodcast.substack.com/subscribe

It's time for another one of our infamous & patented Care/Don't Care Podcasts, with your talent: Eugene S. Robinson, John Nash, & Stephie Haynes. UFC VEGAS 66 RESULTS – Overall, this now 13-bout card saw two exciting first round finishes, four thrilling KO/TKO's, one sweet sub, and seven hard-fought decisions. Rounding things out, our fighters who were awarded for putting forth BONUS efforts included — POTN: Alex Caceres, & Michal Oleksiejczuk. FOTN: Drew Dober vs. Bobby Green. Here's a look at the UFC Vegas 66 fight card, updated records & full results from the event — FIGHT NIGHT MAIN CARD | 7/4PM ETPT 13. Jared Cannonier (16-6) DEF. Sean Strickland (25-5) — via split decision (49-46, 46-49, 49-46) 12. Arman Tsarukyan (19-3) DEF. Damir Ismagulov (24-2) — via unanimous decision (30-27, 30-27, 30-27) 11. Amir Albazi (16-1) DEF. Alessandro Costa (12-3) — via KO (uppercut) at 2:13 of Round 3 10. Alex Caceres (20-13) DEF. Julian Erosa (28-10) — via TKO (left high kick) at 3:04 of Round 1 9. Drew Dober (26-11) DEF. Bobby Green (29-14) — via KO (left hand) at 2:45 of Round 2 8. Michal Oleksiejczuk (18-5) DEF. Cody Brundage (8-3)— via TKO (strikes) at 3:16 of Round 1 PRELIMS 7. Cory McKenna (8-2) DEF. Cheyanne Vlismas (7-3) — via unanimous decision (29-28, 29-28, 29-28) 6. Matthew Semelsberger (11-4) DEF. Jake Matthews (18-6) — via unanimous decision (30-27, 29-28, 29-28) 5. Said Nurmagomedov (17-2) DEF. Saidyokub Kakhramonov (10-3) — via submission (modified guillotine choke) at 3:50 of Round 2 4. Rafa Garcia (15-3) DEF. Hayisaer Maheshate (9-2) — via unanimous decision (30-27, 30-27, 30-27) 3. Rinat Fakhretdinov (21-2) DEF. Bryan Battle (8-2) — via unanimous decision (30-25, 30-25, 30-27) 2. Manel Kape (18-6) DEF. David Dvořák (20-5) — via unanimous decision (30-27, 30-27, 29-28) 1. Sergey Morozov (19-5) DEF. Journey Newson (10-4) — via unanimous decision (30-27, 29-28, 29-28) _____________ UFC Vegas 67: ‘Imavov vs Gastelum' PICKS — At this point in the show we offer you our ‘disclaimer', then our trio will go about predicting the UFC Vegas 67 Fight Night bout sheet. This first event of the new year will take place from the APEX Facility in Vegas, on Sat, Jan 14th., 2023. Here's a look at the fight card & records for the upcoming event via tapology.com, bout order subject to change... UFC Vegas 67 (15 Cares): ESPN+ MAIN CARD | SAT. JAN. 14 — 7/4PM ETPT (12 CARES) 12. Main Event - 185lbs: Kelvin Gastelum (17-8) vs. Nassourdine Imavov (12-3) — At 25:39, 2 Cares (Stephie & Eugene, John abstains on principal) 11. Co-Main - 145lbs: Dan Ige (15-6) vs. Damon Jackson (22-4) — At 24:30, 2 Cares (Stephie & Eugene) 10. 185lbs: Punahele Soriano (9-2) vs. Roman Kopylov (9-2) — At 21:01, 2 Cares (Eugene & Stephie) 9. 135lbs: Ketlen Vieira (13-2) vs. Raquel Pennington (14-8) — At 18:22, 3 Cares 8. 135lbs: Umar Nurmagomedov (15-0) vs. Raoni Barcelos (17-3) — At 15:19, 3 Cares ESPN+ PRELIMS | 4PM/1PM ETPT (3 Cares) 7. 185lbs: Abdul Razak Alhassan (11-5) vs. Claudio Ribeiro (10-2) — At 14:01 6. 155lbs: Mateusz Rębecki (16-1) vs. Nick Fiore (6-0) — At 12:14 5. 135lbs: Mateus Mendonça (10-0) vs. Javid Basharat (13-0) — At 10:37, 1 Care (Stephie) 4. 125lbs: Allan Nascimento (19-6) vs. Carlos Hernandez (8-1) — At 10:22 3. 145lbs: Daniel Argueta (8-1) vs. Isaac Dulgarian (5-0) — At 8:53 2. 125lbs: Jimmy Flick (16-5) vs. Charles Johnson (12-3) — At 7:56, 1 Care (Eugene) 1. 135lbs: Priscila Cachoeira (12-4) vs. Sijara Eubanks (7-7) — At 5:39, 1 Care (Eugene) _____________________ At 29:13 — BONUS OFF TOPIC SEGMENT (Re: Dana White slapping his wife) _____________________ Be sure to follow Eugene on twitter @EugeneSRobinson, John is @heynottheface, and of course you can catch Stephie @CrooklynMMA, and twice a week she's on @LevelChangePod.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. May Beydoun from the Laboratory of Epidemiology and Population Sciences, NIA/NIH/IRP, in Baltimore, MD, discusses a research paper she co-authored that was published by Aging (Aging-US) as the cover for Volume 14, Issue 13, entitled, “Epigenetic clocks and their association with trajectories in perceived discrimination and depressive symptoms among US middle-aged and older adults.” DOI - https://doi.org/10.18632/aging.204150 Corresponding author - May A. Beydoun - baydounm@mail.nih.gov Video version - https://www.youtube.com/watch?v=gkiDhjTL0YY Abstract Background: Perceived discrimination may be associated with accelerated aging later in life, with depressive symptoms acting as potential mediator. Methods: A nationally representative sample of older adults was used [Health and Retirement Study 2010–2016, Age: 50–100 y in 2016, N = 2,806, 55.6% female, 82.3% Non-Hispanic White (NHW)] to evaluate associations of perceived discrimination measures [Experience of discrimination or EOD; and Reasons for Perceived discrimination or RPD) and depressive symptoms (DEP)] with 13 DNAm-based measures of epigenetic aging. Group-based trajectory and four-way mediation analyses were used. Results: Overall, and mostly among female and NHW participants, greater RPD in 2010–2012 had a significant adverse total effect on epigenetic aging [2016: DNAm GrimAge, DunedinPoAm38 (MPOA), Levine (PhenoAge) and Horvath 2], with 20–50% of this effect being explained by a pure indirect effect through DEP in 2014–2016. Among females, sustained elevated DEP (2010–2016) was associated with greater LIN DNAm age (β ± SE: +1.506 ± 0.559, p = 0.009, reduced model), patterns observed for elevated DEP (high vs. low) for GrimAge and MPOA DNAm markers. Overall and in White adults, the relationship of the Levine clock with perceived discrimination in general (both EOD and RPD) was mediated through elevated DEP. Conclusions: Sustained elevations in DEP and RPD were associated with select biological aging measures, consistently among women and White adults, with DEP acting as mediator in several RPD-EPICLOCK associations. Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.204150 Press release - https://www.aging-us.com/news_room/epigenetic-clocks-and-their-association-with-perceived-discrimination-and-depressive-symptoms Keywords - aging, DNA methylation, epigenetic clocks, biological age, perceived discrimination, depressive symptoms About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at https://www.Aging-US.com​​ and connect with us: SoundCloud - https://soundcloud.com/Aging-Us Facebook - https://www.facebook.com/AgingUS/ Twitter - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/agingus​ LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

UFC 268 has us doing our best, worst Al Pacino Godfather Part 3 impression because right when we think we're free of the UFC, they pull us back in! This and more....! ______________________________________ Subscribe to eugenesrobinson.substack.com, follow Eugene on twitter @EugeneSRobinson, on Insta @eugene.s.robinson, PAY here at his Patreon IF you wish: https://www.patreon.com/thestomper Give the live video broadcast of ‘The Show Stomper! Podcast' a “thumbs up”, subscribe and share on The Stomper YT page at: https://youtu.be/zqWfaswpRqw OR: Give the premium video production of the show a “like” and share on The Stomper's Facebook: https://www.facebook.com/stompville/ OR: Listen to premium audio on his... * Spotify: https://open.spotify.com/show/353qdjKsABTte8zQVZCwyd?si=OJjhBfBfTYyYiSZSE5RV0g, * iTunes & Apple TV: https://itunes.apple.com/us/podcast/eugene-s-robinson-show-stomper/id1340723629?mt=2, * iHeartRadio: https://www.iheart.com/podcast/269-eugene-s-robinson-show-sto-30674882/, * OverCast: https://overcast.fm/itunes1340723629/eugene-s-robinson-show-stomper, * PlayerFM: https://player.fm/series/eugene-s-robinson-show-stomper, TuneIn: https://tunein.com/podcasts/Sports--Recreation-Podcasts/Eugene-S-Robinson-Show-Stomper-p1190934/, * Stitcher: https://www.stitcher.com/podcast/the-eugene-s-robinson-show-stomper?refid=stpr, * blubrry: https://www.blubrry.com/eugene_s_robinson_show_stomper/ * or at Amazon Music: https://music.amazon.com/podcasts/31b526af-ea19-4022-ba38-202b583cf8d3/Eugene-S-Robinson-Show-Stomper ________________________________________ Show distribution, graphics & logos via – June M. Williams: https://www.sbnation.com/users/June%2520M.%2520Williams ________________________________________ UFC 268 RESULTS: Overall, this 14-bout card saw two exhilarating first round finishes, seven impressive KO/TKO's, no submissions, and seven hard-fought decisions, one split. Rounding things out, bonuses for putting forth POTN efforts went to Marlon Vera, Chris Barnett, Alex Pereira, and Bobby Green; FOTN honors went to Justin Gaethje vs. Michael Chandler. Here's a look at the UFC 268: ‘KAMARU USMAN VS COLBY COVINGTON 2 & ROSE NAMAJUNAS VS WEILI ZHANG 2' updated fight records & results — ESPN+ PPV MAIN CARD | SAT. NOV 6 At 2:06 — 14. UFC WW Champion Kamaru Usman (20-1) DEF. Colby Covington 2 (16-3) — DEC, Unanimous (49-46, 48-47x2) At 10:59 — 13. UFC SW Champion Rose Namajunas (11-4) DEF. Weili Zhang 2 (21-3) — DEC, SPLIT (48-47, 47-48, 49-46) At 18:56 — 12. Marlon Vera (20-7) DEF. Frankie Edgar (24-10) — KO/TKO, Front Kick at 3:50 of Rd 3, Total 13:50 At 24:59 — 11. Shane Burgos (14-3) DEF. Billy Quarantillo (16-4) — DEC, Unanimous (29-28x3) At 29:36 — 10. Justin Gaethje (23-3) DEF. Michael Chandler (22-7) — DEC, Unanimous (29-28x2, 30-27) ESPN+/ESPNEWS PRELIMS At 36:24 — 9. Alex Pereira (4-1) DEF. Andreas Michailidis (13-5) — KO/TKO, Flying Knee/Punches at 0:18 of Rd 2, Total 5:18 At 42:01 — 8. Bobby Green (28-12) DEF. Al Iaquinta (14-7) — KO/TKO, Jab-Cross/Ground Strikes at 2:25 of Rd 1 At 46:37 — 7. Chris Curtis (27-8) DEF. Phil Hawes (11-3) — KO/TKO, Counter Left at 4:27 of Rd 1 At 53:14 — 6. Nassourdine Imavov (11-3) DEF. Edmen Shahbazyan (11-3) — KO/TKO, Elbows from Crucifix at 4:42 of Rd 2, Total 9:42 At 58:01 — 5. Ian Garry (8-0) DEF. Jordan Williams (9-6) — KO/TKO, Counter Right at 4:59 of Rd 1 ESPN+/UFC FIGHT PASS EARLY PRELIMS At 1:01:00 — 4. Chris Barnett (22-7) DEF. Gian Villante (17-14) — KO/TKO, Spinning Wheel Kick/G&P at 2:23 of Rd 2, Total 7:23 At 1:03:32 — 3. Dustin Jacoby (16-5) DEF. John Allan (13-7) — DEC, Unanimous (29-28x2, 30-27) At 1:04:36 — 2. Melsik Baghdasaryan (7-1) DEF. Bruno Souza (10-2) — DEC, Unanimous (29-28x3) At 1:05:20 — 1. Ode Osbourne (10-4) DEF. C.J. Vergara (9-3) — DEC, Unanimous (28-29x3)

When a 42-year-old man, properly tuned up, meets a body coming through the rye? One of those men must die. Yeah. THAT impressed. ______________________________________ Subscribe to eugenesrobinson.substack.com, follow Eugene on twitter @EugeneSRobinson, on Insta @eugene.s.robinson, PAY here at his Patreon IF you wish: https://www.patreon.com/thestomper Give the live video broadcast of ‘The Show Stomper! Podcast' a “thumbs up”, subscribe and share on The Stomper YT page at: https://youtu.be/ihclK8iL6i8, OR: Give the premium video production of the show a “like” and share on The Stomper's Facebook: https://www.facebook.com/stompville/ OR: Listen to premium audio right here on his SoundCloud OR on his -- * Spotify: https://open.spotify.com/show/353qdjKsABTte8zQVZCwyd?si=OJjhBfBfTYyYiSZSE5RV0g, * iTunes & Apple TV: https://itunes.apple.com/us/podcast/eugene-s-robinson-show-stomper/id1340723629?mt=2, * iHeartRadio: https://www.iheart.com/podcast/269-eugene-s-robinson-show-sto-30674882/, * OverCast: https://overcast.fm/itunes1340723629/eugene-s-robinson-show-stomper, * PlayerFM: https://player.fm/series/eugene-s-robinson-show-stomper, TuneIn: https://tunein.com/podcasts/Sports--Recreation-Podcasts/Eugene-S-Robinson-Show-Stomper-p1190934/, * Stitcher: https://www.stitcher.com/podcast/the-eugene-s-robinson-show-stomper?refid=stpr, * blubrry: https://www.blubrry.com/eugene_s_robinson_show_stomper/ * or at Amazon Music: https://music.amazon.com/podcasts/31b526af-ea19-4022-ba38-202b583cf8d3/Eugene-S-Robinson-Show-Stomper ________________________________________ UFC 267 RESULTS - Overall, this now 14-bout card saw 2 1st Rd finishes, 2 KO/TKO's, 4 subs, & 8 decisions, 1 split. Rounding things out, bonuses for putting forth POTN efforts went to Glover Teixeira and Khamzat Chimaev; FOTN honors went to Petr Yan vs. Cory Sandhagen. Here's a look at the fight card, updated fight records & results — UFC 267: ‘JAN BLACHOWICZ VS GLOVER TEIXEIRA' ESPN+ MAIN CARD | SAT. OCT 30 14. UFC LHW Championship Fight — Glover Teixeira (33-7) DEF. Jan Blachowicz (28-9), SUB, Rear Naked Choke at 3:02 of Rd 2, Total 8:02 13. UFC Interim BW Championship Fight — Petr Yan (16-2) DEF. Cory Sandhagen (14-4), DEC, Unanimous (49-46x3) 12. Islam Makhachev (21-1) DEF. Dan Hooker (21-11) — SUB, Kimura at 2:23 of Rd 1 11. Alexander Volkov (34-9) DEF. Marcin Tybura (22-7) — DEC, Unanimous (30-27x2, 29-28) 10. Khamzat Chimaev (10-0) DEF. Li Jingliang (18-7) — SUB, Rear Naked Choke at 3:16 of Rd 1 9. Magomed Ankalaev (16-1) DEF. Volkan Oezdemir (17-6) — DEC, Unanimous (30-27x2, 29-28) ESPN+ PRELIMS 8. Amanda Ribas (11-2) DEF. Virna Jandiroba (17-3) — DEC, Unanimous (29-28x3) 7. Zubaira Tukhugov (20-5) DEF. Ricardo Ramos (15-4) — DEC, Unanimous (29-28x3) 6. Albert Duraev (15-3) DEF. Roman Kopylov (8-2) — DEC, Unanimous (30-27, 29-27x2) 5. Elizeu Zaleski (23-7) DEF. Benoit St. Denis (8-1) — DEC, Unanimous (29-26x3) 4. Michal Oleksiejczuk (15-4) DEF. Shamil Gamzatov (14-1) — KO/TKO, Uppercut at 3:31 of Rd 1 3. Lerone Murphy (11-0) DEF. Makwan Amirkhani (16-7) — KO/TKO, Knee at 0:14 of Rd 3, Total 14:46 2. Andre Petroski (7-1) DEF. Hu Yaozong (3-3) — SUB, Arm Triangle Choke at 4:46 of Rd 3, Total 14:46 1. Tagir Ulanbekov (13-1) DEF. Allan Nascimento (18-6) — DEC, Split (29-28x2, 28-29) _____________________________ GLOVER TEIXEIRA Championships & Accomplishments: MMA: UFC LHW Championship (One time, current) POTN (Four times) vs. Rashad Evans, Ion Cuțelaba, Anthony Smith, and Jan Błachowicz K/O of the Night (One time) vs. Ryan Bader SUB of the Night (One time) vs. James Te-Huna FOTN (Two times) vs. Ovince Saint Preux and Alexander Gustafsson Most stoppage victories in UFC LHW division Most submission victories in UFC LHW division Oldest First Time Champion Second Oldest Champion, behind Randy Couture Shooto: South America 220-pound Championship (One time)

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.08.06.236596v1?rss=1 Authors: Baranger, D. A., Lindenmuth, M., Nance, M., Guyer, A. E., Keenan, K., Hipwell, A. E., Shaw, D. S., Forbes, E. E. Abstract: Background: The use of functional neuroimaging has been an extremely fruitful avenue for investigating the neural basis of human reward function. This approach has included identification of potential neurobiological mechanisms of psychiatric disease and examination of environmental, experiential, and biological factors that may contribute to disease risk via effects on the reward system. However, a central and largely unexamined assumption of much of this research is that neural reward function is an individual difference characteristic that is relatively stable over time. Methods: In two independent samples of adolescents and young adults studied longitudinally (Ns = 145 & 153, 100% female & 100% male, ages 15-21 & 20-22, 2-4 scans & 2 scans respectively), we tested within-person stability of reward-task BOLD activation, with a median of 1 and 2 years between scans. We examined multiple commonly used contrasts of active states and baseline in both the anticipation and feedback phases of a card-guessing reward task. We examined the effects of cortical parcellation resolution, contrast, network (reward regions and resting-state networks), region-size, and activation strength and variability on the stability of reward-related activation. Results: Overall, stability (ICC; intra-class correlation) across 1-2 years was modest. In both samples, contrasts of an active state relative to a baseline were more stable (e.g., Win>Baseline; mean ICC = 0.13 - 0.33) than contrasts of two active states (e.g., Win>Loss; mean ICC = 0.048 - 0.05). Additionally, activation in reward regions was less stable than in many non-task networks (e.g., dorsal attention), and activation in regions with greater between-subject variability showed higher stability in both samples. Conclusions: These results show that functional neuroimaging activation to reward has modest stability over 1-2 years. Notably, results suggest that contrasts intended to map cognitive function and show robust group-level effects (i.e. Win > Loss) may be less effective in studies of individual differences and disease risk. The robustness of group-level activation should be weighed against other factors when selecting regions of interest in individual difference fMRI studies. Copy rights belong to original authors. Visit the link for more info

  H. Jack West, MD, joins the podcast to discuss the latest trials of immunotherapies in the treatment of lung cancer. Dr. West is an associate clinical professor in medical oncology at City of Hope Comprehensive Cancer Center in Duarte, Calif., and a thought leader in thoracic oncology. Dr. West and Blood & Cancer host David H. Henry, MD, of Pennsylvania Hospital, Philadelphia, review Keynote-042, Keynote-189, and IMpower150, and discuss how the findings influence practice. You can find Dr. West on Twitter at @JackWestMD. Plus, in Clinical Correlation, Ilana Yurkiewicz, MD, of Stanford (Calif.) University, discusses how to be nonjudgmental when talking to patients about how they got cancer. * * * Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019 * * * This Week in Oncology: FDA Approves Ziextenzo for neutropenia-related infection reduction The FDA has approved the biosimilar Ziextenzo to reduce the incidence of infection in patients with nonmyeloid cancer who are receiving suppressive anticancer drugs that are associated with febrile neutropenia. Treatment for metastatic nonsquamous non–small cell lung cancer (NSCLC) without EGFR mutation or ALK translocation: Keynote-042 Design: Pembrolizumab alone vs. chemotherapy alone (carboplatin plus paclitaxel or carboplatin plus pemetrexed) 902 patients 1:1 randomization All patients with at least 1% PDL1 positivity Stratified into three groups: greater than 1%, greater than 20%, and greater than 50% PDL1 score No crossover permitted between groups Results: Overall survival is 16.7 months with pembrolizumab vs. 12.1 months with chemotherapy. PDL1 score 1% or greater: 16.7 months for pembrolizumab vs. 12.1 months for chemotherapy alone. PDL1 score 20% or greater: 17.7 months for pembrolizumab vs. 13.0 months for chemotherapy alone. PDL1 score 50% or greater: 20.0 months for pembrolizumab vs. 12.2 months for chemotherapy alone. There was no statistically significant difference in progression-free survival. Conclusion: Pembrolizumab monotherapy can be extended as first-line therapy to patients with locally advanced or metastatic non–small cell lung cancer and a high PDL1 score. Pembrolizumab monotherapy alone may not be the best choice for patients with a low PLD1 score.   Keynote-189 Design: Pembrolizumab plus chemotherapy vs. placebo plus chemotherapy (pemetrexed plus platinum agent) 616 patients 2:1 randomization All patients with at least 1% PDL1 positivity Crossover to pembrolizumab monotherapy was permitted among the patients in the placebo-combination group who had verified disease progression Results: Overall survival to 12 months: 69.2% with pembrolizumab plus chemotherapy vs. 49.4% with chemotherapy alone. Progression-free survival: 8.8 months with pembrolizumab plus chemotherapy vs. 4.9 months with chemotherapy alone. Conclusion: Pembrolizumab should be added to standard chemotherapy of pemetrexed and a platinum-based drug for significantly longer overall survival and progression-free survival than chemotherapy alone, regardless of level of PDL1 positivity.   IMpower150 Design: Atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) vs. bevacizumab plus carboplatin plus paclitaxel (BCP) vs. atezolizumab plus carboplatin plus paclitaxel (ACP) 1,202 patients 1:1:1 randomization Patients with any PD-L1 immunohistochemistry status were eligible Stratified by level of Teff gene-signature expression Results: Overall survival was longer in the ABCP group than in the BCP group (19.2 months vs. 14.7 months). Progression-free survival was longer in the ABCP group than in the BCP group (8.3 months vs. 6.8 months). In the Teff-high population, progression-free survival was significantly longer in the ABCP group than in the BCP group (11.3 months vs. 6.8 months). Conclusion: Addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NSCLC, regardless of PD-L1 expression. Unclear if ABCP regimen is superior to pembrolizumab monotherapy (in greater than 50% PDL1 group) or pembrolizumab plus pemetrexed plus platinum agent (in all PDL1 groups) as a four-drug regimen may be less attractive than these options. Teff status has not yet been proven to be useful for clinical decision making.   References Mok TSK et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non–small cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819-30.   Gandhi L et al. Pembrolizumab plus chemotherapy in metastatic non–small cell lung cancer. N Engl J Med. 2018;378:2078-92. Socinski MA et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288-301.   Show notes by Sugandha Landy, MD, resident in the department of internal medicine, University of Pennsylvania, Philadelphia.   For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgehemonc Ilana Yurkiewicz on Twitter: @ilanayurkiewicz

Background: This research is an investigation into the role of expert quotes in health news, specifically whether news articles containing a quote from an independent expert are less often exaggerated than articles without such a quote. Methods: Retrospective quantitative content analysis of journal articles, press releases, and associated news articles was performed. The investigated sample are press releases on peer-reviewed health research and the associated research articles and news stories. Our sample consisted of 462 press releases and 668 news articles from the UK (2011) and 129 press releases and 185 news articles from The Netherlands (2015). We hand-coded all journal articles, press releases and news articles for correlational claims, using a well-tested codebook. The main outcome measures are types of sources that were quoted and exaggeration of correlational claims. We used counts, 2x2 tables and odds ratios to assess the relationship between presence of quotes and exaggeration of the causal claim. Results: Overall, 99.1% of the UK press releases and 84.5% of the Dutch press releases contain at least one quote. For the associated news articles these percentages are: 88.6% in the UK and 69.7% in the Netherlands. Authors of the study are most often quoted and only 7.5% of UK and 7.0% of Dutch news articles contained a new quote by an expert source, i.e. one not provided by the press release. The relative odds that an article without an external expert quote contains an exaggeration of causality is 2.6. Conclusions: The number of articles containing a quote from an independent expert is low, but articles that cite an external expert do contain less exaggeration. Bossema FG, Burger P, Bratton L, et al. Expert quotes and exaggeration in health news: a retrospective quantitative content analysis. Wellcome Open Res. 2019;4:56. Published 2019 Jul 8. doi:10.12688/wellcomeopenres.15147.2. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Sections of the Abstract, Introduction, and Conclusion are presented in the Podcast. Link to the full-text article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619368/#ref-24

Association of Multimodal Pain Management Strategies with Perioperative Outcomes and Resource Utilization: A Population-based Study. Memtsoudis SG1, Poeran J, Zubizarreta N, Cozowicz C, Mörwald EE, Mariano ER, Mazumdar M. BACKGROUND: Multimodal analgesia is increasingly considered routine practice in joint arthroplasties, but supportive large-scale data are scarce. The authors aimed to determine how the number and type of analgesic modes is associated with reduced opioid prescription, complications, and resource utilization. METHODS: Total hip/knee arthroplasties (N = 512,393 and N = 1,028,069, respectively) from the Premier Perspective database (2006 to 2016) were included. Analgesic modes considered were opioids, peripheral nerve blocks, acetaminophen, steroids, gabapentin/pregabalin, nonsteroidal antiinflammatory drugs, cyclooxygenase-2 inhibitors, or ketamine. Groups were categorized into "opioids only" and 1, 2, or more than 2 additional modes. Multilevel models measured associations between multimodal analgesia and opioid prescription, cost/length of hospitalization, and opioid-related adverse effects. Odds ratios or percent change and 95% CIs are reported. RESULTS: Overall, 85.6% (N = 1,318,165) of patients received multimodal analgesia. In multivariable models, additions of analgesic modes were associated with stepwise positive effects: total hip arthroplasty patients receiving more than 2 modes (compared to "opioids only") experienced 19% fewer respiratory (odds ratio, 0.81; 95% CI, 0.70 to 0.94; unadjusted 1.0% [N = 1,513] vs. 2.0% [N = 1,546]), 26% fewer gastrointestinal (odds ratio, 0.74; 95% CI, 0.65 to 0.84; unadjusted 1.5% [N = 2,234] vs. 2.5% [N = 1,984]) complications, up to a -18.5% decrease in opioid prescription (95% CI, -19.7% to -17.2%; 205 vs. 300 overall median oral morphine equivalents), and a -12.1% decrease (95% CI, -12.8% to -11.5%; 2 vs. 3 median days) in length of stay (all P < 0.05). Total knee arthroplasty analyses showed similar patterns. Nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors seemed to be the most effective modalities used. CONCLUSIONS: While the optimal multimodal regimen is still not known, the authors' findings encourage the combined use of multiple modalities in perioperative analgesic protocols. DOI: 10.1097/ALN.0000000000002132

Background: Laser lithotripsy is an established endourological modality. Ho:YAG laser have broadened the indications for ureteroscopic stone managements to include larger stone sizes throughout the whole upper urinary tract. Aim of current work is to assess efficacy and safety of Ho: YAG laser lithotripsy during retrograde ureteroscopic management of ureteral calculi in different locations. Methods: 88 patients were treated with ureteroscopic Ho: YAG laser lithotripsy in our institute. Study endpoint was the number of treatments until the patient was stone-free. Patients were classified according to the location of their stones as Group I (distal ureteric stones, 51 patients) and group II (proximal ureteral stones, 37). Group I patients have larger stones as Group II (10.70 mm vs. 8.24 mm, respectively, P = 0.020). Results: Overall stone free rate for both groups was 95.8%. The mean number of procedures for proximal calculi was 1.1 +/- 0.1 (1-3) and for distal calculi was 1.0 +/- 0.0. The initial treatment was more successful in patients with distal ureteral calculi (100% vs. 82.40%, respectively, P = 0.008). No significant difference in the stone free rate was noticed after the second laser procedure for stones smaller versus larger than 10 mm (100% versus 94.1%, P = 0.13). Overall complication rate was 7.9% (Clavien II und IIIb). Overall and grade-adjusted complication rates were not dependant on the stone location. No laser induced complications were noticed. Conclusions: The use of the Ho: YAG laser appears to be an adequate tool to disintegrate ureteral calculi independent of primary location. Combination of the semirigid and flexible ureteroscopes as well as the appropriate endourologic tools could likely improve the stone clearance rates for proximal calculi regardless of stone-size.

Background and Objective: The estimation of dietary intake remains a challenge in human nutritional studies. In infants, the use of food diaries (FDs) is a suitable method already validated; however, this method is not exempt from error. In formula-fed infants, dilution of powdered formulas may produce errors. Our aim was to develop and validate standard operating procedures (SOPs) for the assessment of dietary intake in formula-fed infants, attending potential sources of error. Methods: We analysed sources of error in a random subsample of 3-day FDs from 100 infants enrolled in the European Childhood Obesity Project. Calculations to estimate intakes were standardised and included in a software tool (SOPsystem). An evaluation of a simulated FD was performed by 9 trained nutritionists and 23 nutrition students (n = 225 and n = 575 bottle evaluations, respectively) to compare the results obtained when using or not the SOPsystem. Correct answers (%), coefficients of variation, and the time spent (minutes) to assess the simulated FD were analysed. Results: Overall, 60% of the FDs contained reports of incorrect volumes, and 37% reported incorrect formula dilutions. When the SOPsystem was used, correct answers in the simulated FD were more frequent (P < 0.001) and the mean coefficient of variation and the time spent were lower (P < 0.005 and P < 0.01, respectively). Conclusions: The development and implementation of SOPs with a software tool that identifies specific sources of error in record-keeping achieved a harmonised and improved process for assessing dietary intakes in formula-fed infants, minimising errors in calculations and reducing the work time invested.

Background: Europe faces an enormous public health challenge with aging populations and rising cancer incidence. Little is known about what concerns the public across European countries regarding cancer care towards the end of life. We aimed to compare the level of public concern with different symptoms and problems in advanced cancer across Europe and examine factors influencing this. Methods: Telephone survey with 9,344 individuals aged >= 16 in England, Flanders, Germany, Italy, Netherlands, Portugal and Spain. Participants were asked about nine symptoms and problems, imagining a situation of advanced cancer with less than one year to live. These were ranked and the three top concerns examined in detail. As `burden to others' showed most variation within and between countries, we determined the relative influence of factors on this concern using GEE and logistic regression. Results: Overall response rate was 21%. Pain was the top concern in all countries, from 34% participants (Italy) to 49% (Flanders). Burden was second in England, Germany, Italy, Portugal, and Spain. Breathlessness was second in Flanders and the Netherlands. Concern with burden was independently associated with age (70+ years, OR 1.50; 95%CI 1.24-1.82), living alone (OR 0.82, 95%CI 0.73-0.93) and preferring quality rather than quantity of life (OR 1.43, 95%CI 1.14-1.80). Conclusions: When imagining a last year of life with cancer, the public is not only concerned about medical problems but also about being a burden. Public education about palliative care and symptom control is needed. Cancer care should include a routine assessment and management of social concerns, particularly for older patients with poor prognosis.

Objective: To validate the prognostic value of preoperative levels of CYFRA 21-1, CEA and the corresponding tumor marker index (TMI) in patients with stage I non-small cell lung cancer (NSCLC). Methods: Two hundred forty stage I NSCLC patients (80 in pT1 and 160 in pT2; 100 squamous cell carcinomas, 91 adenocarcinomas, 32 large-cell carcinomas, 17 with other histologies; 171 males and 69 females) who had complete resection (R0) between 1986 and 2004 were included in the analysis. CYFRA 21-1 and CEA were measured using the Elecsys system (Roche) and AxSym-System (Abbott), respectively. Univariate analysis was performed using the Kaplan-Meier method to identify potential associations between survival and age, gender, CYFRA 21-1, CEA and TMI. Results: Overall 3- and 5-year survival rates were 74 and 64%, respectively. Male gender (p = 0.0009) and age 1 70 years (p = 0.0041) were associated with a worse prognosis; there were no differences between pT1 and pT2 nor between histological subtypes. Three- year survival was 72% for CYFRA 21-1 levels > 3.3 ng/ml versus 75% for levels 6.7 ng/ ml versus 75% for CEA 70 years were associated with a worse outcome, but elevated levels of CEA and CYFRA 21-1, and TMI risk were not. Copyright (C) 2008 S. Karger AG, Basel.

Objective: To assess the role of foot dermatomycosis ( tinea pedis and onychomycosis) and other candidate risk factors in the development of acute bacterial cellulitis of the leg. Methods: A case-control study, including 243 patients ( cases) with acute bacterial cellulitis of the leg and 467 controls, 2 per case, individually matched for gender, age (+/-5 years), hospital and admission date (+/-2 months). Results: Overall, mycology-proven foot dermatomycosis was a significant risk factor for acute bacterial cellulitis (odds ratio, OR: 2.4; p < 0.001), as were tinea pedis interdigitalis (OR: 3.2; p < 0.001), tinea pedis plantaris (OR: 1.7; p = 0.005) and onychomycosis (OR: 2.2; p < 0.001) individually. Other risk factors included: disruption of the cutaneous barrier, history of bacterial cellulitis, chronic venous insufficiency and leg oedema. Conclusions: Tinea pedis and onychomycosis were found to be significant risk factors for acute bacterial cellulitis of the leg that are readily amenable to treatment with effective pharmacological therapy. Copyright (C) 2004 S. Karger AG, Basel.

Background: Infliximab, a chimeric anti-tumour necrosis factor monoclonal antibody with potent anti-inflammatory effects, represents an effective treatment option in patients with severe inflammatory bowel disease (IBD). Serious side-effects of such an immunomodulating therapy are speculated and therefore we reviewed our clinical experience in a retrospective safety study looking upon a single cohort of 100 IBD patients from a large German University Hospital. Methods: 100 patients with severe Crohn's disease (n = 92), ulcerative colitis (n = 7) or indeterminate colitis (n = 1) treated with infliximab (5 mg/kg) from January 2000 to December 2003 were retrospectively analysed for acute and subacute adverse events by chart review. Results: Overall, infliximab therapy was generally well tolerated. No fatal complications, malignancies, autoimmune diseases, neurologic or cardiovascular complications were observed in the cohort during the study period. Overall, adverse events were observed in 10 patients: 2 patients showed an acute infusion reaction, 1 patient a serum sickness-like reaction, in 4 patients a bacterial or viral infection occurred, in 1 patient pancytopenia and 2 patients developed surgical complications. Only 6 patients with adverse events required admission to hospital. A case of tuberculosis after infliximab was not found. The lack of adverse side-effects was associated with young median age and infrequent comorbidities of the cohort. Conclusion: Regarding its strong immunomodulating capacity, infliximab appears to be an efficient and relatively safe therapeutic option for patients with severe IBD. However, the use of infliximab requires careful screening and close patient monitoring to identify patients at risk and the infrequent, but sometimes serious complications of infliximab. Copyright (C) 2004 S. Karger AG, Basel.